Results 41 to 50 of about 1,429,326 (362)
Nilotinib-Associated Destructive Thyroiditis
Case Reports in Endocrinology, 2015 Protein tyrosine kinase inhibitors are currently an important drug class in the treatment of leukemia. They represent targeted cancer therapy and have become the treatment of choice in chronic myeloid leukemia.
Suhalia Bakerywala +4 more
doaj +1 more source
Technology in Cancer Research & Treatment, 2020 Background: The efficacy of next-generation epidermal growth factor receptor-tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer who have failed first-generation epidermal growth factor receptor-tyrosine kinase inhibitors ...
Yi-Tian Qi MM +2 more
doaj +1 more source
Advances in studies of tyrosine kinase inhibitors and their acquired resistance
Molecular Cancer, 2018 Protein tyrosine kinase (PTK) is one of the major signaling enzymes in the process of cell signal transduction, which catalyzes the transfer of ATP-γ-phosphate to the tyrosine residues of the substrate protein, making it phosphorylation, regulating cell ...
Qinlian Jiao +5 more
semanticscholar +1 more source
Receptor Tyrosine Kinase-Targeted Cancer Therapy
International Journal of Molecular Sciences, 2018 In the past two decades, several molecular targeted inhibitors have been developed and evaluated clinically to improve the survival of patients with cancer. Molecular targeted inhibitors inhibit the activities of pathogenic tyrosine kinases. Particularly,
T. Yamaoka +4 more
semanticscholar +1 more source
Pyk2 is a Novel Tau Tyrosine Kinase that is Regulated by the Tyrosine Kinase Fyn
Journal of Alzheimer’s Disease, 2018 The protein tyrosine kinase Pyk2 is encoded by PTK2B, a novel Alzheimer’s disease (AD) susceptibility variant, with the PTK2B risk allele being associated with increased mRNA levels, suggestive of increased Pyk2 levels. However, the role of Pyk2, a member of the focal adhesion kinase (FAK) family, in AD pathology and its regulation are largely unknown.
Chuanzhou Li +2 more
openaire +5 more sources
Interactions between Two Cytoskeleton-associated Tyrosine Kinases: Calcium-dependent Tyrosine Kinase and Focal Adhesion Tyrosine Kinase [PDF]
Journal of Biological Chemistry, 1999 The calcium-dependent tyrosine kinase (CADTK), also known as Pyk2/RAFTK/CAKbeta/FAK2, is a cytoskeleton-associated tyrosine kinase. We compared CADTK regulation with that of the highly homologous focal adhesion tyrosine kinase (FAK). First, we generated site-specific CADTK mutants.
Ruth Chen Dy +4 more
openaire +2 more sources
Receptor tyrosine kinases in carcinogenesis
Oncology Letters, 2016 [This retracts the article DOI: 10.3892/ol.2016.5200.].
Pei-Ying Zhang, Xiao-Ying Zhang
openaire +5 more sources
Discovery of a Novel, Potent, and Src Family-selective Tyrosine Kinase Inhibitor
Journal of Biological Chemistry, 1996 Here, we have studied the activity of a novel protein-tyrosine kinase inhibitor that is selective for the Src family of tyrosine kinases. We have focused our study on the effects of this compound on T cell receptor-induced T cell activation, a process ...
J. Hanke +7 more
semanticscholar +1 more source
Second-generation inhibitors of Bruton tyrosine kinase
Journal of Hematology & Oncology, 2016 Bruton tyrosine kinase (BTK) is a critical effector molecule for B cell development and plays a major role in lymphoma genesis. Ibrutinib is the first-generation BTK inhibitor.
Jingjing Wu +3 more
semanticscholar +1 more source
Insights into PI3K/AKT signaling in B cell development and chronic lymphocytic leukemia
FEBS Letters, EarlyView.This Review explores how the phosphoinositide 3‐kinase and protein kinase B pathway shapes B cell development and drives chronic lymphocytic leukemia, a common blood cancer. It examines how signaling levels affect disease progression, addresses treatment challenges, and introduces novel experimental strategies to improve therapies and patient outcomes.
Maike Buchner
wiley +1 more source